Hailey Hall, MD
Maternal & Fetal Medicine · Houston, TXNPI 1821293499
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,400 of the $3,207 with a category attached, or 74.8%. Myriad Women's Health, Inc. accounts for 76.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $2,552 and has fallen 95.6% since, to $113 in 2025. Among maternal & fetal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $66.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Women's Health, Inc.$2K
- AbbVie$172
- Exeltis, USA Inc.$110
- Astellas Pharma US Inc$104
- Sumitomo Pharma America, Inc.$89
- Hologic Sales And Service, LLC$60
- plus $206 from 7 others
What the payments were for
- Speaking & faculty fees$2,40075%
- Food & beverage$80725%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Women's Health, Inc. | 4 | $2,467 |
| AbbVie(2 entities) | 11 | $172 |
| Exeltis, USA Inc. | 6 | $110 |
| Astellas Pharma US Inc | 5 | $104 |
| Sumitomo Pharma America, Inc. | 5 | $89 |
| Hologic Sales And Service, LLC | 4 | $60 |
| Mayne Pharma Commercial LLC | 2 | $43 |
| Bayer | 2 | $41 |
| Coopersurgical, Inc. | 3 | $38 |
| Organon | 3 | $27 |
| Myovant Sciences Inc. | 1 | $25 |
| Pfizer | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$2,400
How this compares
$3,207 in reported general payments places this provider in the 90th percentile of 228 maternal & fetal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 18 | $1,542 |
| ValacyclovirValacyclovir Hcl | 17 | $347 |
Paid to pharmacies, not to this prescriber.
Other maternal & fetal medicine in Houston
- Baha SibaiHouston$132K
- Jimmy EspinozaHouston$79K
- Sean BlackwellHouston$16K
- Saul SnowiseHouston$15K
- Anushka ChelliahHouston$8K
- Lara FrielHouston$5K
- Brian KirshonHouston$5K
- Karin FoxHouston$4K
- Irene StaffordHouston$4K
- Ignatia van Den VeyverHouston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.